Gene therapy for liver disease: The power of protecting new ideas (Guest blog)
At the heart of the Vivet story is the vision to match cutting-edge science with an unmet medical need. The team began with a mission: to develop liver gene therapies for orphan diseases – rare conditions for which there are currently no treatments.
‘We have developed unique assets, as optimised construct for our Wilson VTX-801 product, that ensure the treatment is effective in the right cells with the highest possible gene expression,’ he says. ‘And, crucially, we are also progressing on making this effect durable.’
As encouraging as these breakthroughs may be, investors committing millions of euro need to be sure that Vivet won’t simply be overtaken by copycats before they have a chance to turn science into sales. ‘To attract funding, we needed to be in control over our own destiny; to control our products,’ says Combal. ‘This means having full intellectual property protection and freedom to operate.’